title: [Use of instenon in complex treatment of patients with optic nerve atrophy caused by craniocerebral trauma].
abstract: Instenon, a combined nootropic agent, was used on the step-type basis within a complex treatment of optic nerve atrophy caused by craniocerebral trauma. Our study revealed that instenon, when used within a complex treatment of a partial optic nerve atrophy caused by craniocerebral trauma, improved the visual acuity in 85.7% of patients and it expanded the total visual field in 76.2% of patients, whereas the routine therapy ensured the related improvements in 58.9% and 61.5% of patients, respectively. Besides, the drug provided for a better retinal electric sensitivity and for a better optic nerve conduction in 73.8% of cases versus 64.1% of cases with basic therapy. Increased velocity parameters in the ocular-artery blood flow were registered in 77.1%, of patients who received instenon, by duplex scanning.
authors.forename: M T
authors.initials: MT
authors.lastname: Aznabaev
authors.forename: V A
authors.initials: VA
authors.lastname: Khalikov
authors.forename: A Sh
authors.initials: ASh
authors.lastname: Zagidullina
mesh_terms: D000293:Adolescent; D000328:Adult; D001549:Benzamides / Q000008:administration & dosage / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D006259:Craniocerebral Trauma / Q000150:complications*; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006592:Hexobendine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000008:administration & dosage / Q000627:therapeutic use; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009880:Ophthalmic Artery / Q000000981:diagnostic imaging / Q000502:physiology; D009896:Optic Atrophy / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy*; D009900:Optic Nerve / Q000502:physiology; D010277:Parasympathomimetics / Q000008:administration & dosage / Q000627:therapeutic use; D012160:Retina / Q000502:physiology; D013806:Theophylline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013997:Time Factors; D018616:Ultrasonography, Doppler, Duplex; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000627:therapeutic use; D014792:Visual Acuity; D014794:Visual Fields
chemical_list: D001549:Benzamides; D004338:Drug Combinations; D018697:Nootropic Agents; D010277:Parasympathomimetics; D014748:Vinca Alkaloids; D009388:Neostigmine; C013983:vinpocetine; C001453:Instenon; D006592:Hexobendine; D013806:Theophylline